Gain-of-Function Research: Science, Risk, and Governance
In 2012, two research groups reported H5N1 systems that transmitted between ferrets by the respiratory route. One study identified a small set of changes associated with that phenotype, but ferret transmission is not equivalent to efficient human transmission and the modified system did not reproduce the full severity profile implied by confirmed human H5N1 case data. The studies nevertheless forced a durable policy question: when an experiment creates a plausible new hazard, what evidence is sufficient to show that its expected public-health value exceeds accident, misuse, and information risks?
Decision-makers who need the handbook-wide overview should start with the Executive Summary, which places gain-of-function oversight alongside DNA synthesis screening, AI evaluation, and BWC implementation priorities.
- Understand what gain-of-function (GOF) research is and why it is controversial.
- Evaluate the H5N1 ferret transmissibility studies that sparked the 2012 debate.
- Analyze the 2014-2017 U.S. moratorium and the P3CO framework.
- Assess the scientific benefits versus biosecurity risks of GOF research.
- Identify alternatives to GOF research (field surveillance, reverse genetics, computational modeling).
- Recognize the ethical and policy challenges in regulating dual-use research.
This chapter discusses biosecurity risks at a conceptual level appropriate for education and policy analysis. Consistent with responsible information practices:
- Omitted: Actionable protocols, specific synthesis routes, exact pathogen sequences
- Included: Risk frameworks, governance mechanisms, policy recommendations
For detailed biosafety protocols, consult your Institutional Biosafety Committee and relevant regulatory guidance.
Introduction
Gain-of-function research remains one of biosecurity’s most contested categories. The scientific argument is that experimental changes can clarify mechanisms relevant to emergence and countermeasure research. The governance argument is that some experiments create new accident and misuse hazards before their promised benefits have been demonstrated.
The disagreement cannot be resolved by labels alone. “Gain of function” describes many ordinary experiments, while policy concern concentrates on a narrower set of activities that could plausibly create severe, widely transmissible, countermeasure-resistant, or otherwise consequential hazards. Assessment therefore belongs at the level of the proposed phenotype, experimental system, evidence of benefit, available alternatives, containment, personnel reliability, and communication plan.
Gain-of-Function Research Defined
Definition
Gain-of-function (GOF) research involves genetically altering organisms to give their gene products new or enhanced capabilities. In the biosecurity context, GOF specifically refers to experiments that enhance a pathogen’s:
- Transmissibility: Making it spread more easily (e.g., airborne transmission)
- Virulence: Increasing disease severity or lethality
- Host range: Enabling infection of new species (e.g., making avian virus infect mammals)
Not all GOF research is controversial. Enhancing antibiotic resistance in E. coli to study resistance mechanisms does not by itself raise the same biosecurity concern. The concern focuses on potential pandemic pathogens (PPPs), organisms that could cause widespread, uncontrollable human disease.
Technical Approaches
GOF studies can use animal models, sequence analysis, non-replicating systems, and other molecular approaches. This chapter does not reproduce method-level instructions, mutation combinations, or construct designs. The governance question is whether a proposed activity creates a consequential phenotype and whether the same question can be answered with a lower-risk system.
The H5N1 Controversy: Spark That Ignited the Debate
Background: H5N1 Avian Influenza
H5N1 highly pathogenic avian influenza emerged in 1996. Key characteristics:
- In birds: Spreads efficiently, devastates poultry flocks
- In humans: Confirmed cases have had a high case-fatality proportion, but the estimate varies with case definition, surveillance, and time period (CDC surveillance data).
- Transmission barrier: Rare human infections, almost always from direct bird contact. Limited human-to-human spread
The nightmare scenario: What if H5N1 evolved to spread efficiently between humans while maintaining its high lethality? You’d have a disease more transmissible than seasonal flu with lethality rivaling Ebola.
The Fouchier and Kawaoka Studies (2012)
In late 2011, two independent research groups announced they’d made H5N1 transmissible between mammals via respiratory route.
Fouchier et al. (Erasmus Medical Center): Published in Science, June 2012. The study reported respiratory transmission between ferrets after serial experimental adaptation. The result was a model-specific phenotype, not evidence of efficient human transmission. This chapter intentionally omits mutation-level details; readers seeking the governance history should consult Dual-Use Research of Concern.
Kawaoka et al. (University of Wisconsin / University of Tokyo): Published in Nature, May 2012. The study used a different experimental system and also reported respiratory transmission between ferrets. The two systems were not interchangeable, and neither established a human-transmission phenotype.
Both studies used ferrets because they are a commonly used model for respiratory influenza (Herfst et al., 2012). Ferret transmission can inform mechanistic hypotheses, but it does not establish human transmissibility.
Critics argued that publication lowered barriers by combining a concerning phenotype with procedural and sequence-level detail. Defenders countered that the findings could inform surveillance and countermeasure research. The public-health value and information hazard must be assessed together, and the outcome does not justify reproducing operational details in this chapter.
The Publication Controversy
Before publication, both manuscripts went to the U.S. National Science Advisory Board for Biosecurity (NSABB) for review. NSABB initially recommended redacting key experimental details: publish the findings, but not the methods.
Outcry from scientific community: redaction would undermine peer review, reproducibility, and scientific progress. After further review and researchers providing additional context, NSABB reversed its recommendation. Both papers published in full.
The voluntary 60-day moratorium in early 2012 by 39 influenza researchers (including Fouchier and Kawaoka) demonstrated scientific community’s awareness of the controversy. Moratorium letter stated they would pause research to allow time for discussion of benefits and risks.
The 2014-2017 U.S. Funding Pause
Trigger: Biosafety Incidents
In October 2014, the U.S. government implemented a funding pause (HHS announcement) on new GOF research involving influenza, MERS, and SARS viruses.
Immediate triggers were biosafety lapses at federal facilities: - CDC anthrax exposure incident (June 2014) - Discovery of forgotten smallpox vials at NIH (July 2014) - CDC cross-contamination of H5N1 samples (July 2014)
These incidents raised concerns: if federal BSL-3/BSL-4 labs had safety problems, were we confident about oversight of enhanced pathogen research across all institutions?
Scope of the Pause
The moratorium targeted research “reasonably anticipated to”: - Enhance pathogenicity or transmissibility of influenza, MERS, or SARS viruses - Make these viruses transmissible via respiratory route in mammals
Key limitation: applied only to new federally funded research. Ongoing projects could continue. Non-federally-funded research was not covered.
The pause aimed to provide time for: - Risk-benefit analysis of GOF research - Development of comprehensive federal policy - Assessment of adequate oversight mechanisms
The Three-Year Wait
From October 2014 to December 2017, no new federal funding for covered GOF research. Scientists conducting this work either: - Pivoted to non-GOF projects - Found non-federal funding - Waited for policy resolution
Critics argued the pause was too long and stifled important research. Defenders said three years was necessary for thorough deliberation on managing catastrophic risks.
The P3CO Framework (2017-2025)
HHS P3CO: Enhanced Potential Pandemic Pathogens
In December 2017, HHS released the Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens (P3CO = Potential Pandemic Pathogen Care and Oversight).
Enhanced PPP (ePPP) definition: A pathogen that has been enhanced to be: 1. Highly transmissible: Likely highly transmissible and capable of wide, uncontrollable spread in human populations 2. Highly virulent: Likely to cause significant morbidity and/or mortality in humans
If proposed research is “reasonably anticipated” to create, transfer, or use an ePPP, it triggers P3CO review before funding.
Review Process
P3CO established multi-level review:
Institutional level: - Institutional biosafety committees (IBCs) review protocols - Assess biosafety and biosecurity measures - Determine if research meets ePPP criteria
Federal level: - HHS conducts department-level multidisciplinary review - Scientific merit assessment - Public health benefit evaluation - Biosafety and biosecurity risk assessment - Mitigation strategy review - Final funding decision by HHS
Criteria for approval: Research must demonstrate: - Significant scientific and public health benefits - Risks can be adequately mitigated - No reasonable alternatives exist that pose less risk
Limitations of P3CO
Opacity: Critics noted the review process lacked transparency. Which projects were reviewed? Which approved or denied? Minimal public reporting. A GAO investigation validated that critique, finding HHS does not consistently share key details about how it assesses and mitigates risks in high-risk pathogen research. The report recommended regular public reporting on review outcomes, mitigation steps, and the number of supported higher-risk projects (GAO-26-107348).
HHS-only: Only HHS developed GOF review process. Other agencies funding life sciences research (DOD, DHS, USDA) had no equivalent framework.
Voluntary for non-federal: Private or foreign-funded research not covered.
Narrow scope: Focused on specific pathogens (influenza, MERS, SARS coronaviruses). What about other potential pandemic pathogens?
The 2024 Policy: Superseding P3CO
In May 2024, a new U.S. government policy for oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential was released by the White House Office of Science and Technology Policy.
This policy aimed to address P3CO limitations by: - Broadening scope beyond original three pathogen families - Expanding to all federally funded research (multi-agency) - Increasing transparency in review process - Clarifying Enhanced PPP (now called PEPP) definitions
Status through August 3, 2026: Executive Order 14292 triggered regulatory action just before the 2024 policy’s scheduled May 6, 2025 effective date. NIH NOT-OD-25-112 rescinded the NIH implementation notice for the 2024 DURC/PEPP framework. NIH then issued NOT-OD-25-127, terminating specified foreign support and suspending other covered NIH funding and support until the new policy is implemented. NIH’s public policy-change register does not list a later replacement through August 3, 2026 (NIH, 2026). The operative question for a project is therefore not whether P3CO “nominally” returned, but which current agency instruction, award term, institutional rule, and jurisdictional requirement applies.
The Scientific Case FOR Gain-of-Function Research
Argument 1: Anticipating Natural Evolution
Proponents argue GOF research identifies mutations that could arise naturally, allowing preemptive action.
Example: The H5N1 ferret studies identified phenotypic and sequence signals that can inform surveillance. Surveillance programs can monitor naturally circulating viruses for relevant changes without recreating the experimental system (NIH statement).
Without GOF research, we’d only discover dangerous combinations after human pandemic begins.
Argument 2: Vaccine and Therapeutic Development
Understanding mechanisms of virulence and transmission accelerates countermeasure development.
Vaccine targets: GOF studies identify which viral proteins are critical for pandemic potential. Target vaccines at those proteins.
Animal models: Enhanced viruses that can infect standard lab animals (mice, ferrets) can enable testing vaccines and drugs that otherwise could not be evaluated, when the natural virus does not infect those species efficiently.
Historical precedent: Many successful vaccines (polio, measles) involved modifying viruses, some through processes classifiable as GOF (attenuating by passage, introducing mutations).
Argument 3: Basic Science Value
Fundamental understanding of host-pathogen interactions, immune evasion, and viral evolution has applications beyond specific pandemic threats.
Insights from influenza GOF inform coronaviruses, and vice versa. General principles of viral adaptation benefit entire field.
The Scientific Case AGAINST Gain-of-Function Research
Argument 1: Lab Accidents Happen
Even with best practices, biosafety incidents occur. CDC, USAMRIID, and other elite facilities have documented lapses.
Risk calculation: Quantitative estimates of laboratory-accident probability depend on the facility population, activity, denominator, and reporting assumptions. They should be treated as scenario analyses rather than universal rates. The relevant governance question is whether the proposed benefit can justify the residual risk after alternatives and controls are considered.
Gryphon Scientific’s 2016 risk assessment commissioned during the moratorium found significant uncertainties in both risk and benefit estimates, noting that benefits were often overstated while risks were underappreciated.
Critics argue that researchers are creating risks nature has not yet produced, in settings where a release could affect dense populations.
Argument 2: Overstated Benefits
Surveillance argument weak: Monitoring for a laboratory-defined phenotype assumes a future pandemic will follow that evolutionary path. Nature might take a different route. Signals associated with the ferret studies have appeared in circulating strains, but the complete experimental phenotype has not been observed in wild-bird surveillance. The research therefore remains a model-specific signal, not a forecast.
Vaccine development alternatives: Reverse genetics can create safer vaccine candidates without enhancing pandemic potential. Field surveillance of circulating strains provides real-world data better than lab-generated threats.
Animal model assumption: Transmission in ferrets does not mean transmission in humans. Ferret models are proxies, not proof.
Argument 3: Dual-Use Information Risk
Publishing GOF methods can disclose procedural details, sequence-level information, and evidence that a particular approach produced a concerning phenotype. A sophisticated actor could use such information alongside materials, facilities, tacit expertise, and independent validation. The information is inherently dual-use, so publication decisions should disclose the scientific conclusion while limiting unnecessary operational detail.
Argument 4: Alternatives Exist
Field surveillance, computational modeling, reverse genetics for vaccine development, and pseudovirus systems can provide significant pandemic preparedness benefits without creating enhanced pathogens.
Many influenza researchers argue that field surveillance, basic epidemiology, and veterinary monitoring of animal reservoirs provide pandemic preparedness benefits with substantially lower biosecurity risks than creating enhanced pathogens in laboratory settings.
The 2001 anthrax attacks originated from a U.S. biodefense lab, not external terrorists. The perpetrator was a microbiologist with authorized access to select agents. GOF research can create new hazards and train researchers in methods that have dual-use implications. Even strong biosafety controls do not eliminate insider risk. Background checks, personnel reliability programs, and security culture reduce risk but cannot eliminate it.
Alternatives to Gain-of-Function Research
Field Surveillance and Genomic Epidemiology
Monitor naturally circulating viruses in animal reservoirs and humans:
Advantages: - Studies real-world evolution, not lab artifacts - Identifies actual threats, not hypothetical ones - Lower biosafety risk (studying natural isolates at BSL-2 or BSL-3, not enhanced versions at BSL-3 or BSL-4)
Examples: - GISAID database tracking influenza and coronavirus evolution globally - Veterinary surveillance of avian influenza in wild birds and poultry - Syndromic surveillance detecting unusual respiratory disease patterns
Limitations: - Reactive rather than anticipatory - Requires extensive global infrastructure - May miss rare combinations that could emerge
Reverse Genetics for Vaccine Development
Reverse-genetics vaccine research can use attenuated or replication-limited systems without enhancing pandemic potential. The relevant safeguards are activity-specific design review, containment, institutional oversight, and validation that the candidate remains within the intended risk envelope. This is often described as gain-of-attenuation rather than gain-of-danger.
Advantages: - Directly produces public health tool (vaccine) - Lower biosecurity risk (making pathogens less dangerous, not more) - Established regulatory pathway
Computational Modeling and Bioinformatics
Analyze sequence databases to predict: - Which sequence features may be associated with altered transmissibility - Host receptor binding changes - Immune escape variants
Advantages: - No wet lab work, no biosafety risk - Can analyze thousands of hypothetical variants rapidly - Increasingly accurate with AI/ML advances (AlphaFold for structure prediction)
Limitations: - Predictions need experimental validation - Models only as good as training data (which comes from… experimental research) - Cannot fully replace empirical biology
Pseudovirus Systems
Create replication-defective viral particles that mimic aspects of target virus:
How it works: - Take envelope proteins from pathogen of interest (e.g., H5N1 HA) - Package into replication-incompetent vector backbone (e.g., VSV, lentivirus) - Resulting particle has the target virus’s surface but cannot reproduce beyond one infection cycle
Advantages: - Safe to work with (BSL-2 instead of BSL-3/4) - Can study receptor binding, entry mechanisms, antibody neutralization - No risk of creating transmissible pandemic virus
Limitations: - Does not fully recapitulate real virus behavior - Cannot study replication, immune evasion beyond entry, or transmission
Ethical and Policy Challenges
The Dual-Use Dilemma
GOF research illustrates the dual-use problem: the same information can benefit public health and enable harm. Publication decisions require calibrated review because knowledge cannot be made available to legitimate researchers without some risk of misuse.
Open science tradition: Reproducibility, peer review, and cumulative knowledge require sharing methods and data.
Security imperative: Some information may be too dangerous to disseminate widely.
No consensus on how to balance these values.
Global Governance Gaps
P3CO and 2024 U.S. policy only cover federally funded U.S. research. GOF experiments can occur: - In other countries with different (or no) oversight - With private funding - In academic-industry partnerships
Pandemic threats do not respect borders. A laboratory accident in any country can affect the world, but national sovereignty limits international regulation.
Biological Weapons Convention prohibits bioweapons but has no verification mechanism and does not explicitly regulate GOF research.
Scientific Freedom vs. Public Safety
Researchers argue for autonomy in choosing research questions and methods. Governments and publics expect protection from catastrophic risks created by research.
Where’s the line? Who decides?
- Should review be institutional (scientists governing scientists)?
- Governmental (democratic accountability)?
- International (global risks require global oversight)?
No system satisfies everyone.
Current State and Future Outlook
The fifteen-month governance vacuum that followed Executive Order 14292 has closed. The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026, prohibits federal support for dangerous gain-of-function research conducted in the United States and abroad, requires independent review for other high-risk life sciences research, and restricts federal funding to institutions and countries lacking adequate biosafety and oversight standards. NIH issued implementing notice NOT-OD-26-101 the same day.
The policy is not yet operative. Agencies were given 90 days to stand up a single independent third-party review body and 120 days to publish implementation guidance, with the policy taking effect in mid-November 2026. Until agency guidance is published, investigators should apply the current terms of their award and obtain institutional and agency determinations rather than assuming either the 2017 P3CO framework or the new policy automatically governs a given project. Key research areas affected include: - SARS-CoV-2 variant studies - High-risk influenza adaptation experiments - Coronavirus host range investigations
In October 2022, Boston University researchers reported a chimeric SARS-CoV-2 study that drew scrutiny over construct choice, containment, and interpretation. Media descriptions overstated the findings, illustrating why governance analysis should rely on the primary paper and distinguish animal-model outcomes from human risk.
- P3CO oversight: Did research require pre-approval? NIH found BU should have disclosed to them; BU believed institutional approval sufficient.
- Definitional ambiguity: Is this GOF if the chimera was less lethal than parent strain?
- Transparency: Preprint publication before NIH awareness raised questions about oversight effectiveness.
The incident highlighted continued gaps in P3CO framework application and fueled calls for clearer, mandatory oversight standards.
Transparency remains limited: Public information about the number and disposition of GOF proposals is incomplete. A January 2026 GAO report (GAO-26-107348) found that HHS does not consistently share key details about how risks of high-risk pathogen research are assessed and mitigated, and recommended greater disclosure of risk-review processes. Limited transparency hinders informed debate.
International landscape: China, Russia, and other countries conduct GOF research with varying levels of oversight. U.S. restrictions may simply shift research to less-regulated jurisdictions.
COVID-19 origins debate: Whether SARS-CoV-2 emerged from natural spillover or lab-related incident remains unresolved. The lab leak hypothesis (whether from GOF research or not) has intensified scrutiny of all laboratory pathogen research.
Technological change: Easier genetic engineering (CRISPR), cheaper DNA synthesis, AI-assisted design all make GOF experiments more accessible. Oversight mechanisms designed for 2017 technology may not adequately address 2024 capabilities.
Demonstrated (supported by published evidence or official records):
- GOF experiments can create airborne-transmissible H5N1 in ferrets (Herfst et al. 2012, Imai et al. 2012)
- Enhanced pathogens can be created in BSL-3+ containment
- Laboratory biosafety incidents occur at documented rates across all biosafety levels
- The 2017 P3CO framework established an enhanced federal funding-review process, and the 2025 executive order and NIH notices changed the current funding posture
- Alternatives (field surveillance, computational modeling, pseudovirus systems) provide some pandemic preparedness benefits
Contested (experts disagree):
- Whether GOF research provides unique pandemic preparedness benefits unavailable through alternatives
- Whether accident risks outweigh knowledge benefits
- Whether information hazards from publication are significant given other sources
- Whether ferret transmission results predict human pandemic potential
Unknown (insufficient evidence to assess):
- Total global GOF research activity (much is not publicly reported)
- Actual laboratory accident rates for GOF experiments (underreporting likely)
- Whether SARS-CoV-2 originated from laboratory research (origin remains unresolved)
- Effectiveness of P3CO framework in preventing concerning research
The GOF debate reflects genuine scientific uncertainty combined with value differences about acceptable risk. Neither “always safe” nor “never justified” captures the complexity.
What is gain-of-function research in biosecurity?
Gain-of-function (GOF) research enhances a pathogen’s transmissibility, virulence, or host range to study pandemic potential and develop countermeasures. The controversy focuses on experiments with potential pandemic pathogens that could cause catastrophic disease if released.
What were the H5N1 ferret studies and why were they controversial?
In 2012, Fouchier and Kawaoka independently reported H5N1 systems that transmitted between ferrets by the respiratory route. The studies raised concerns about publishing methods that could be misused, while proponents argued that the findings could inform surveillance and countermeasure research. Ferret transmission and human case-fatality estimates should not be combined into a claim about human pandemic behavior.
What is the P3CO framework?
The HHS P3CO (Potential Pandemic Pathogen Care and Oversight) framework, implemented in 2017 after a 2014-2017 funding pause, provides multi-level review for research reasonably anticipated to create enhanced potential pandemic pathogens. It requires demonstration of significant public health benefits, adequate risk mitigation, and absence of reasonable lower-risk alternatives.
What are safer alternatives to gain-of-function research?
Alternatives include field surveillance of naturally circulating viruses, reverse genetics for vaccine development without enhancing pandemic potential, computational modeling using AI to predict dangerous mutations, pseudovirus systems that are replication-defective, and in vitro protein studies. These provide pandemic preparedness benefits with substantially lower biosecurity risks.
This chapter is part of The Biosecurity Handbook. For handbook-wide priorities, see the Executive Summary.